Almirall, S.A.

ALM

ES0157097017

Pharmaceuticals

Market Closed - BME Other stock markets 11:35:09 2024-06-21 am EDT			5-day change	1st Jan Change
9.62 ^EUR	-2.19%		-2.38%	+14.18%

Jun. 10	Almirall: extension of indication in actinic keratosis	CF
Jun. 10	Almirall’s Skin Disease Drug Gets US FDA Nod for Larger Treatment Area	MT

Almirall Wins GBP 12.4 Million Multiple Awardees Contract for Supplying Analgesic, Anaesthetic, Musculoskeletal and Joint Disease Medicines

January 10, 2016 at 05:26 pm EST

Almirall, Uxbridge, won a GBP 12.4 million (excluding VAT) multiple awardees contract award from the Common Services Agency (the Authority) for the supply of a range of analgesic, anaesthetic, musculoskeletal and joint disease medicines (All other Analgesic, Anaesthetic Musculoskeletal and Joint Disease Medicines) (Contract Award Notice No.: 2016/S 005-005020; Lot No.: 7).

Latest news about Almirall, S.A.

Almirall: extension of indication in actinic keratosis	Jun. 10	CF
Almirall’s Skin Disease Drug Gets US FDA Nod for Larger Treatment Area	Jun. 10	MT
FDA Approves Almirall's Klisyri®? (Tirbanibulin) for the Treatment of Actinic Keratosis on Expanded Area of Face or Scalp Up to 100 Cm2	Jun. 10	CI
Global markets live: Pfizer, Chevron, Amazon, Booking, Apple, Novavax, SoftBank...	May. 13
Almirall confirms full-year targets despite higher first-quarter costs	May. 13	RE
Almirall: share price rises after 'solid' start to the year	May. 13	CF
European shares listless as investors brace for inflation test	May. 13	RE
Transcript : Almirall, S.A., Q1 2024 Earnings Call, May 13, 2024	May. 13
Almirall, S.A. Reiterates Earnings Guidance for Full Year 2024	May. 13	CI
Almirall, S.A. Approves Distribution of Dividend	May. 13	CI
Almirall, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 12	CI
Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment	Mar. 13	MT
Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB...	Feb. 19
Almirall: share price surges after agreement with Novo Nordisk	Feb. 19	CF
Transcript : Almirall, S.A., 2023 Earnings Call, Feb 19, 2024	Feb. 19
Almirall Secures Global Rights for Blocking Monoclonal Antibody Under Deal with Novo Nordisk	Feb. 19	MT
Almirall S.A. Enters into an Exclusive License Agreement with Novo Nordisk	Feb. 19	CI
Almirall, S.A. Provides Earnings Guidance for the Year 2024	Feb. 19	CI
Almirall, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 18	CI
Transcript : Almirall, S.A. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:00 AM	Jan. 09
Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases	Dec. 21	CI
Almirall: messenger RNA alliance with Belgium's etherna	Dec. 12	CF
Almirall Collaborates with etherna on Development of Severe Skin Disease Therapies	Dec. 12	MT
Almirall and Etherna Enter into A Multi-Target Alliance to Develop mRNA-Based Therapies in Medical Dermatology	Dec. 12	CI
Certain Shares of Almirall, S.A. are subject to a Lock-Up Agreement Ending on 10-DEC-2023.	Dec. 09	CI

Chart Almirall, S.A.

Duration

Period

More charts

Company Profile

Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.

Sector

Pharmaceuticals

Calendar

2024-07-21 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Almirall, S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.62 EUR

Average target price

11.46 EUR

Spread / Average Target

+19.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ALMIRALL, S.A.	+14.18%	2.15B
ELI LILLY AND COMPANY	+51.63%	796B
NOVO NORDISK A/S	+41.51%	628B
JOHNSON & JOHNSON	-5.10%	358B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+9.95%	301B
ASTRAZENECA PLC	+17.66%	244B
ROCHE HOLDING AG	+3.39%	228B
NOVARTIS AG	+10.75%	214B
AMGEN INC.	+6.99%	165B

Other Pharmaceuticals

Almirall, S.A.

Equities

ALM

ES0157097017

Pharmaceuticals

Almirall Wins GBP 12.4 Million Multiple Awardees Contract for Supplying Analgesic, Anaesthetic, Musculoskeletal and Joint Disease Medicines

EPS Revisions